Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4564195 | 0.88 | RIPK1 (0.48) | UCHL1LMNATSHRNPC1ALDH1A1 | |
| SCHEMBL29747367 | 0.84 | UCHL1 (0.48) | UCHL1LMNATSHRNR1H2NPC1 | |
| SCHEMBL16881401 | 0.83 | ALDH1A1 (0.44) | UCHL1LMNATSHRNPC1ALDH1A1 | |
| SCHEMBL26985093 | 0.83 | TSHR (0.42) | UCHL1LMNATSHRNPC1ALDH1A1 | |
| SCHEMBL30679850 | 0.82 | ALOX5AP (0.45) | UCHL1LMNATSHRNPC1ALDH1A1 | |
| SCHEMBL31290628 | 0.82 | USP30 (0.47) | UCHL1LMNATSHRNR1H2NPC1 | |
| SCHEMBL26987927 | 0.82 | USP30 (0.47) | UCHL1LMNATSHRNR1H2NPC1 | |
| SCHEMBL31226409 | 0.82 | ALOX5AP (0.45) | UCHL1LMNATSHRNPC1ALDH1A1 | |
| SCHEMBL31226469 | 0.82 | ALOX5AP (0.45) | UCHL1LMNATSHRNPC1ALDH1A1 | |
| SCHEMBL3312132 | 0.81 | NR1H2 (0.57) | UCHL1LMNATSHRNR1H2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353862-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2025-11-20 | — | — | US | disclosed |
| US-12404283-B2 | c-MYC mRNA translation modulators and uses thereof in the treatment of cancer | ANIMA BIOTECH INC. (US) | 2025-09-02 | — | — | US | disclosed |
| EP-4547671-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | Anima Biotech Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| EP-4547672-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | Anima Biotech Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20250129100-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2025-04-24 | — | — | US | disclosed |
| WO-2024010762-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| WO-2024010761-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| WO-2024010761-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| WO-2024010762-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2024-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129100-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | MYC, MYCBP, MYCBP2 | UCHL1 3900/4885LMNA 1484/4885TSHR 3934/4885 |
| US-20250353862-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | MYC, MYCBP, MYCBP2 | UCHL1 3900/4885LMNA 1484/4885TSHR 3934/4885 |
| US-12404283-B2 | c-MYC mRNA translation modulators and uses thereof in the treatment of cancer | MYC, MYCBP, MYCBP2 | UCHL1 3900/4885LMNA 1484/4885TSHR 3934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.